Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial  by Dearnaley, David et al.
www.thelancet.com/oncology   Vol 13   January 2012 43
Articles
Lancet Oncol 2012; 13: 43–54
Published Online
December 13, 2011 
DOI:10.1016/S1470-
2045(11)70293-5 
See Comment page 5
Royal Marsden NHS 
Foundation Trust, London, UK 
(Prof D Dearnaley FRCR, 
M Bidmead MSc, 
Prof A Horwich FRCR, 
R Huddart FRCR, V Khoo MD, 
O Naismith MSc, C Parker FRCR, 
C South MSc); The Institute of 
Cancer Research, London, UK 
(Prof D Dearnaley, G Sumo MSc, 
A Gao MSc, S Hassan MSc, 
Prof A Horwich, R Huddart, 
V Khoo, E Hall PhD); 
Clatterbridge Centre for 
Oncology NHS Foundation 
Trust, Wirral, UK 
(I Syndikus FRCR, H Mayles MSc, 
P Mayles PhD); Brighton and 
Sussex University Hospitals, 
Brighton, UK 
(D Bloomﬁ eld FRCR); Royal 
Surrey County Hospital, 
Guildford, UK (C Clark PhD); 
Addenbrooke’s Hospital, 
Cambridge, UK 
(H Patterson FRCR); Beatson 
West of Scotland Cancer 
Centre, Glasgow, UK 
(M Russell FRCP); Ipswich 
Hospital, Ipswich, UK 
(C Scrase FRCR); Cardiﬀ  
University, Cardiﬀ , UK 
(J Staﬀ urth MD); and Sheﬃ  eld 
Teaching Hospitals Foundation 
Trust, Sheﬃ  eld, UK 
(P Kirkbride FRCR)
Correspondence to:
Prof David Dearnaley, 
Department of Academic 
Radiotherapy, The Royal Marsden 
Hospital, Surrey SM2 5PT, UK
david.dearnaley@icr.ac.uk
Conventional versus hypofractionated high-dose intensity-
modulated radiotherapy for prostate cancer: preliminary 
safety results from the CHHiP randomised controlled trial
David Dearnaley, Isabel Syndikus, Georges Sumo, Margaret Bidmead, David Bloomﬁ eld, Catharine Clark, Annie Gao, Shama Hassan, 
Alan Horwich, Robert Huddart, Vincent Khoo, Peter Kirkbride, Helen Mayles, Philip Mayles, Olivia Naismith, Chris Parker, Helen Patterson, 
Martin Russell, Christopher Scrase, Chris South, John Staﬀ urth, Emma Hall
Summary
Background Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of 
hypofractionated treatment. We present a pre-planned preliminary safety analysis of side-eﬀ ects in stages 1 and 2 of a 
randomised trial comparing standard and hypo fractionated radiotherapy.
Methods We did a multicentre, randomised study and recruited men with localised prostate cancer between Oct 18, 
2002, and Aug 12, 2006, at 11 UK centres. Patients were randomly assigned in a 1:1:1 ratio to receive conventional or 
hypofractionated high-dose intensity-modulated radio therapy, and all were given with 3–6 months of neoadjuvant 
androgen suppression. Computer-generated random permuted blocks were used, with risk of seminal vesicle 
involvement and radiotherapy-treatment centre as stratiﬁ cation factors. The conventional schedule was 37 fractions 
of 2 Gy to a total of 74 Gy. The two hypofractionated schedules involved 3 Gy treatments given in either 20 fractions to 
a total of 60 Gy, or 19 fractions to a total of 57 Gy. The primary endpoint was proportion of patients with grade 2 or 
worse toxicity at 2 years on the Radiation Therapy Oncology Group (RTOG) scale. The primary analysis included all 
patients who had received at least one fraction of radiotherapy and completed a 2 year assessment. Treatment 
allocation was not masked and clinicians were not blinded. Stage 3 of this trial completed the planned recruitment in 
June, 2011. This study is registered, number ISRCTN97182923.
Findings 153 men recruited to stages 1 and 2 were randomly assigned to receive conventional treatment of 74 Gy, 
153 to receive 60 Gy, and 151 to receive 57 Gy. With 50·5 months median follow-up (IQR 43·5–61·3), six (4·3%; 
95% CI 1·6–9·2) of 138 men in the 74 Gy group had bowel toxicity of grade 2 or worse on the RTOG scale at 2 years, 
as did ﬁ ve (3·6%; 1·2–8·3) of 137 men in the 60 Gy group, and two (1·4%; 0·2–5·0) of 143 men in the 57 Gy group. 
For bladder toxicities, three (2·2%; 0·5–6·2) of 138 men, three (2·2%; 0·5–6·3) of 137, and none (0·0%; 
97·5% CI 0·0–2·6) of 143 had scores of grade 2 or worse on the RTOG scale at 2 years.
Interpretation Hypofractionated high-dose radiotherapy seems equally well tolerated as conventionally frac tionated 
treatment at 2 years.
Funding Stage 1 was funded by the Academic Radiotherapy Unit, Cancer Research UK programme grant; stage 2 was 
funded by the Department of Health and Cancer Research UK.
Introduction
Prostate cancer is the most common cancer in men in 
the UK, USA, and western Europe, with 37 000 men 
diagnosed in the UK and an estimated 913 000 cases 
worldwide in 2008.1 After the introduction of prostate-
speciﬁ c antigen (PSA) testing, most men diagnosed have 
localised disease. Management options include external-
beam radiotherapy, brachytherapy, radical prostatectomy, 
active surveillance (for men with low-risk disease), and 
watchful waiting (for those unsuitable for radical curative 
treatment). External-beam radiotherapy might be most 
appropriate for men with disease features of intermediate 
or high risk,2,3 and is associated with long-term disease 
control in most patients.4 About 10 000 men receive 
radical prostate radiotherapy in the UK every year.5
Substantial technological advances over the past decade 
have improved both the ability to adjust dose distributions 
to the prostate target and treatment accuracy. Several 
phase 3 randomised control trials have shown the beneﬁ t 
of dose escalation,6 and high-dose conformal radiotherapy 
with conventional 2 Gy daily fractions to a total dose of 
74 Gy has become the standard of care in the UK.7
Additionally, there has been interest in the fraction 
sensitivity of prostate cancer.8–10 The α-β ratio for most 
cancers is believed to be about 10 Gy, but for prostate 
cancer values as low as 1·5 Gy have been suggested, 
which is smaller than the roughly 3 Gy reported for the 
late reactions of most normal tissues (including rectum).11 
These ﬁ ndings have potentially important therapeutic 
implications. Hypofractionated radiotherapy with fewer 
high-fraction-size treatments would be beneﬁ cial for 
prostate cancer because it would deliver a larger 
biological-equivalent dose to the tumour than would 
conventional treatment in 1·8–2·0 Gy fractions, while 
Articles
44 www.thelancet.com/oncology   Vol 13   January 2012
maintaining a similar or lower incidence of late normal 
tissue reactions. Furthermore, improved resource use 
and patient convenience because of short treatment 
duration would be important gains.
Maintenance of few treatment-related side-eﬀ ects is 
of paramount importance, because they increase with 
dose escalation. In previous dose-escalation randomised 
controlled trials (with diﬀ erences of 8–10 Gy between 
groups), variations in side-eﬀ ects of 10–15% have been 
reported.6 Meta-analysis showed an odds ratio of 
1·58 for late gastrointestinal toxicity of grade 2 or more, 
in favour of conventional rather than high-dose 
radiotherapy.6 We therefore aimed to compare a con-
ventional radiotherapy schedule with hypofractionated 
schedules in prostate cancer.
Methods
Trial design
We undertook a multistage, multicentre randomised 
controlled trial (Conventional or Hypofractionated 
High-dose Intensity Modulated Radiotherapy in Prostate 
Cancer; CHHiP). We used a three-arm design to ensure 
that we would be able to extrapolate an isoeﬀ ective dose 
for a speciﬁ c rate of complications (in a similar way to 
the large UK breast fractionation trials).12 Biological 
doses in the experimental schedules were calculated to 
be equivalent to those in the conventional schedule; 
equivalence was achieved with the assumptions that 
α-β ratios were 2·5 Gy for the 60 Gy group and 1·5 Gy 
for the 57 Gy group.9 All treatment groups received 
conformal and intensity-modulated radiation techniques. 
This report is a pre-planned analysis of stages 1 and 2 of 
this trial, with the object ive of establishing the safety of 
experimental hypofractionated radiotherapy schedules.
Patients
Patients were recruited to stage 1 between Oct 18, 2002 and 
April 27, 2005, at the Royal Marsden NHS Trust (London, 
UK) and Clatterbridge Centre for Oncology NHS 
Foundation Trust (Wirral, UK); and to stage 2 between 
May 4, 2005, and Aug 12, 2006, at 11 UK centres (see 
appendix). Men with histologically conﬁ rmed T1B–T3A N0 
M0 prostate cancer,13 PSA concentrations of less than 
30 ng/mL, estimated risk of lymph-node involvement less 
than 30%,14 and WHO performance status 0 or 1 were 
eligible. Patients were excluded if they had T3 tumours 
and a Gleason score of 8 or more, a life expectancy of less 
than 10 years, previous pelvic radiotherapy, previous 
androgen suppression, another active malignancy in the 
past 5 years (other than cutaneous basal-cell carcinoma), 
comorbid conditions precluding radical radiotherapy, full 
anticoagulation treatment, or hip prosthesis.
CHHiP (CRUK/06/016) was approved by the London 
Multi-centre Research Ethics Committee (04/MRE02/10) 
and the local ethics committees of all participating 
centres. It was sponsored by the Institute of Cancer 
Research and was done in accordance with the principles 
of good clinical practice. All patients provided written 
informed consent. The trial was coordinated by the Royal 
Marsden Hospital Bob Champion Unit (Sutton, UK) and 
the Institute of Cancer Research Clinical Trials and 
Statistics Unit (ICR-CTSU; Sutton, UK), in which central 
statistical monitoring and all analyses were done. The trial 
management group was overseen by an independent trial 
steering committee. Emerging safety and eﬃ  cacy data 
were reviewed regularly in conﬁ dence by the independent 
data monitoring committee. Both committees approved 
reporting of this pre-planned analysis of side-eﬀ ect data 
to 2 years from patients recruited in stages 1 and 2.
Randomisation and masking
Men were registered in the trial before or after starting 
initial hormone therapy. Patients were randomly assigned 
(in a 1:1:1 ratio) 4–6 weeks before radiotherapy. Independent 
randomisation was via telephone to the ICR-CTSU. 
Computer-generated random permuted blocks were used; 
stratiﬁ cation was by risk of seminal vesicle involvement14 
and radiotherapy treatment centre. Treatment allocation 
was not masked and, because of the trial’s size, assessors 
could not be blinded to toxicity or clinical assessments.
Treatment
As part of standard treatment, men received short-course 
androgen suppression for 3–6 months before and during 
radiotherapy, although it was optional for men with 
low-risk disease. Injections of a luteinising-hormone-
releasing hormone (LHRH) analogue every month, 
combined with initial antiandrogen to reduce testosterone 
ﬂ are, or an antiandrogen alone, were allowed.
Individuals in the control group received prostate 
radiotherapy with standard 2 Gy daily fractions (Monday 
to Friday treatment) for 7·4 weeks to give a total dose of 
74 Gy in 37 fractions. Patients in the experimental groups 
were given hypofractionated treatment with 3 Gy daily 
fractions to a total dose of either 60 Gy in 20 fractions in 
4·0 weeks or 57 Gy in 19 fractions in 3·8 weeks. Planning 
of radiotherapy treatment for all three groups was done 
with forward or inverse three-dimensional methods about 
12 weeks after start of hormonal treatment. A complex 
forward-planned multisegment technique was developed 
for the trial.15 Target and treatment planning volumes 
have been previously described.15 Treatment was planned 
and delivered using an integrated simultaneous-boost 
technique with target volumes designed to give the 
conventional 74 Gy group: a dose of 59 Gy (80%) to the 
prostate and base or all seminal vesicles, with a uniform 
1·0 cm margin; a dose of 71 Gy (96%) to the prostate with 
a 1·0 cm margin, except posteriorly where the margin 
was reduced to 0·5 cm; and 74 Gy (100%) to the prostate 
with a margin of 0·5 cm (0·0 cm posteriorly). Target 
volumes had to be covered by the 95% isodose. Pelvic 
lymph nodes were not included in the target volumes.
For the hypofractionated groups, similar proportions of 
the prescribed dose (ie, 60 Gy or 57 Gy) were given to 
See Online for appendix
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outer target volumes. Mandatory dose constraints were 
deﬁ ned for both target coverage and avoidance of normal 
tissues including rectum, bowel, bladder, and femoral 
heads. Treatment was delivered with 6–15 MV photons 
with multileaf collimators to shape beams. Portal imaging 
was used to verify treatment accuracy, which was to be 
within 3 mm. 
A quality-assurance programme was designed as an 
integral part of the study. Before trial entry began, every 
centre completed a process document that deﬁ ned 
the methods to be used for CT simulation, treatment 
planning, and veriﬁ ed treatment accuracy and dosimetry. 
This document was reviewed and reﬁ ned as necessary by 
the trial’s quality-assurance physicist. The chief investigator 
and quality-assurance physicist reviewed target and normal 
tissue outlining for the ﬁ rst two or three patients entered 
by each centre. They gave detailed individual feedback and 
outlines were modiﬁ ed when necessary before patients 
were treated. During the trial, on-site quality-assurance 
visits measured the accuracy of treatment delivery and 
dosimetry with a trial-speciﬁ c phantom. Details of target 
volumes, dose parameters, constraints, and the proforma 
used to record each patient’s dose distribution are given in 
the appendix.
Assessments
Staging investigations included PSA measurement, 
standard haematology and biochemistry, lymph-node 
assessment by pelvic MRI or CT, and bone scan for patients 
at intermediate or high risk.2,3 Histology was locally 
assessed with diagnostic transrectal ultrasound-guided 
biopsies (or specimens from transurethral resection of the 
prostate) and reported with the Gleason system.
Bowel, bladder, and sexual function assessments were 
made before hormone therapy (when the patient was 
already registered for the trial); before radiotherapy; every 
week during radiotherapy; and at weeks ten, 12, and 18 to 
assess acute toxicity, with subsequent assessments at 
26 weeks and every 6 months for 5 years. Initial symptoms 
and radiotherapy side-eﬀ ects were graded with the Late 
Eﬀ ects on Normal Tissues: Subjective/Objective/
Management (LENT/SOM)16 and Royal Marsden Hospital 
(RMH)17 scoring systems. Radiotherapy side-eﬀ ects were 
also graded with the Radiation Therapy Oncology Group 
(RTOG) scoring system.18
Statistical analysis
Stage 1 included 150 patients (50 per treatment group) and 
was powered (87·8% power; 0·045 one-sided α) with a 
one-stage Fleming-A’Hern design19 to rule out an upper 
limit of 25% of patients with RTOG grade 2 or worse 
bladder or bowel complications at 2 years for each 
experimental group, with an expected rate of 10% in the 
control group. If seven or more patients of 45 patients 
assessed at 2 years had grade 2 or worse complications, 
then the study arm was to be rejected. Stage 2 was similarly 
powered to rule out an upper limit of 20% of patients with 
RTOG grade 2 or worse bowel or bladder complications at 
Figure 1: Trial proﬁ le for CHHiP stages 1 and 2
A complete set of follow-up forms means that the patient completed 6, 12, 18, and 24 month follow-up forms; follow-up forms completed after 2 years not 
included. RTOG=Radiation Therapy Oncology Group. RT=radiotherapy. 
153 allocated to 60 Gy in 20 daily fractions of 3 Gy
457 patients randomised
6 did not receive treatment
    1 ineligible
    4 technically unsuitable
    1 unknown
147 received allocated treatment
         147 had planned dose
10 not evaluable for RTOG 
       toxicity at 2 years
       1 died
       1 withdrew consent
       2 lost to follow-up       
       4 missing forms
       2 missing data
137 evaluable for RTOG toxicity at 2 years
         134  complete set of follow-up forms
              3  missed some assessments
153 allocated to 74 Gy in 37 daily fractions of 2 Gy
4 did not receive treatment
    1 ineligible
    1 technically unsuitable
    2 patient choice
149 received allocated treatment
         148 had planned dose
               1 less than planned dose
11 not evaluable for RTOG 
      toxicity at 2 years
      4 died
      1 withdrew consent
      5 missing forms
      1 missing data
138 evaluable for RTOG toxicity at 2 years
         132 complete set of follow-up forms
              6  missed some assessments
151 allocated to 57 Gy in 19 daily fractions of 3 Gy
3 did not receive treatment
    2 ineligible
    1 unknown
148 received allocated treatment
         148 had planned dose
5 not evaluable for RTOG 
    toxicity at 2 years
    2 died
    1 lost to follow-up       
    2 missing forms
143 evaluable for RTOG toxicity at 2 years
         138  complete set of follow-up forms
              5   missed some assessments
For more on the phantom see 
http://www.rttrialsqa.org.uk
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2 years. In each treatment group, 135 evaluable patients 
were needed (95·2% power; 0·049 one-sided α). If 20 or 
more patients in one group developed compli cations of 
grade 2 or more at 2 years, the study arm was to be rejected. 
The sample size (stage 1 plus stage 2) was set at 450 patients 
(150 per group), with a 10% allowance for dropout.
Analyses of side-eﬀ ect data for prevalence were done 
according to treatment received and—with the exception 
of com parisons at 18 weeks—included all available 
assessments from all patients who received at least one 
fraction of radiotherapy. The 18 week comparison was 
restricted to assessments done in a period 2 weeks either 
side of this time to consistently capture the end of the 
acute toxicity period across treatment groups.
For the primary endpoint, only patients with an RTOG 
assessment at 2 years were included in analyses, 
although we did a sensitivity analysis that included all 
patients. Proportions of patients with RTOG toxicity of 
grade 2 or worse at 2 years (the primary endpoint) are 
presented with exact binomial 95% CIs. Exploratory 
analyses were done to compare the side-eﬀ ect proﬁ le 
between the randomised treatment groups. Scores 
before and after treatment were compared with the 
Wilcoxon signed-rank test. Time to ﬁ rst occurrence of 
late (reported on follow-up forms from 6 months after 
the start of radiotherapy onwards) side-eﬀ ects of diﬀ erent 
grades were compared with the Kaplan-Meier method 
used to calculate cumulative proportion of patients that 
had events by 2 years. Cox proportional hazards models 
were used to estimate and test the eﬀ ect of the 
experimental treatments against the control group. A 
hazard ratio (HR) of less than one favoured the 
experimental group. Analyses presented in this report 
have not been adjusted for stratiﬁ cation factors, but 
sensitivity analyses adjusting for risk group showed the 
results to be robust (data not shown).
Analyses were based on a database snapshot on 
April 1, 2010, and were done with STATA version 11·2. 
This study is registered, number ISRCTN97182923.
Role of the funding source
The funding source provided peer-reviewed approval for 
the trial, but had no other role in study design, collection, 
analysis, interpretation of data, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication. GS, SH, and EH also had full 
access to the data.
Results
457 men were recruited (ﬁ gure 1). 13 patients received 
no radiotherapy: four were ineligible at trial entry, ﬁ ve 
were shown to be technically unsuitable during the 
planning process, two patients chose to leave, and two 
for unknown reasons. Of the patients who were 
technically unsuitable, two had large amounts of small 
bowel in the target volume, two had small bladders, and 
74 Gy in 37 
fractions (n=153)
60 Gy in 
20 fractions 
(n=153)
57 Gy in 
19 fractions 
(n=151)
Median age (years) 68 (64–72, 51–80) 68 (63–71, 56–82) 67 (62–72, 44–80)
T stage
T1a/T1b/T1c/T1x 47 (31%) 69 (45%) 64 (42%)
T2a/T2b/T2c/T2x 91 (59%) 72 (47%) 74 (49%)
T3a/T3x 15 (10%) 12 (8%) 13 (9%)
Gleason score
≤6 56 (37%) 67 (44%) 57 (38%)
7 92 (60%) 81 (53%) 86 (57%)
8 5 (3%) 5 (3%) 8 (5%)
PSA (ng/mL)
Median (IQR) 10 (8–16) 13 (9–17) 12 (8–16)
Mean (SD) 12 (6) 14 (7) 13 (7)
PSA (ng/mL)
0·0–4·99 9 (6%) 6 (4%) 12 (8%)
5·0–9·99 61 (40%) 47 (31%) 43 (28%)
10·0–19·99 65 (42%) 74 (48%) 71 (47%)
20·0–49·99 18 (12%) 26 (17%) 25 (17%)
Pretreatment seminal vesicle risk group12
Low 35 (23%) 38 (25%) 37 (25%)
Medium 118 (77%) 115 (75%) 114 (75%)
Clinical history
Diabetes 11 (7%) 15 (10%) 15 (10%)
Hypertension 55 (36%) 47 (31%) 50 (33%)
Inﬂ ammatory bowel or diverticular 
disease
5 (3%) 6 (4%) 5 (3%)
Previous pelvic surgery 13 (8%) 8 (5%) 5 (3%)
Symptomatic haemorrhoids in past 
12 months
14 (9%) 9 (6%) 16 (11%)
Any previous TURP 18 (12%) 15 (10%) 8 (5%)
NCCN risk group
Low 22 (14%) 23 (15%) 13 (9%)
Intermediate 94 (61%) 90 (59%) 97 (64%)
High 36 (24%) 39 (25%) 40 (26%)
Unknown* 1 (<1%) 1 (<1%) 1 (<1%)
Hormone therapy
LHRH analogue with short-term 
antiandrogens
143 (93%) 143 (93%) 140 (93%)
150 mg bicalutamide every day† 8 (5%) 10 (7%) 11 (7%)
Other 2 (1%) 0 (0%) 0 (0%)
Median duration of hormone treatment 
(days)
150 (125–179) 146 (124–167) 149 (124–177)
Median time from androgen suppression 
to start of radiotherapy (days)‡
111 (98–131) 111 (98–132) 111 (98–134)
Median time from randomisation to 
start of radiotherapy (days)‡
47 (30–68) 51 (35–71) 49 (35–71)
Median radiotherapy treatment length 
(days)‡
53 (51–55) 28 (27–29) 27 (26–28)
Data are n (%), median (IQR, range), or median (IQR). TURP=transurethral resection of the prostate. NCCN=National 
Comprehensive Cancer Network. LHRH=luteinising-hormone-releasing hormone *Unknown because of clinical 
T-stage T1a, T2x and T3x. †Given before and during treatment, and for 2 months after end of radiotherapy. ‡Data 
presented for patients who started radiotherapy (n=149 in the 74 Gy group, n=147 in the 60 Gy group, and n=148 in 
the 57 Gy group).
Table 1: Baseline demographic and clinical characteristics and treatment details by allocated 
treatment group
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one had a large prostate. Overall,  six patients were 
ineligible: one had abnormal blood counts, two were 
receiving warfarin, one had stage T3b disease, one had 
hip prostheses, and one had a perianal ﬁ stula (two 
ineligible patients did receive radiotherapy). Of the 
444 treated patients, all but one received the protocol-
assigned radiotherapy dose and schedule; one patient 
in the 74 Gy group stopped treatment after 70 Gy 
because of acute urinary obstruction.
Median follow-up is 50·5 months (IQR 43·5–61·3); 426 
of 457 patients randomly assigned and 424 of 444 treated 
have been followed up for at least 2 years. Baseline charac-
teristics were evenly distributed across treatment groups 
(table 1). Patients received a median of 16 weeks 
(14·0–18·9) hormonal treatment before radiotherapy. 
Most patients received LHRH analogues and short-term 
antiandrogens (table 1), similarly distributed across 
treatment groups and by risk group of the National 
Comprehensive Cancer Network.
Acute bowel and bladder side-eﬀ ects, measured with 
the RTOG scale, seemed to peak sooner in the ex-
perimental groups than in the control group (ﬁ gure 2): at 
4–5 weeks in the hypofractionated groups compared with 
7–8 weeks in the control group. Of 129 patients in the 
74 Gy group who were assessed 18 weeks after start of 
radiotherapy, three (2·3%) reported bowel side-eﬀ ects of 
RTOG grade 2 or worse and nine (7·0%) had bladder 
side-eﬀ ects of grade 2 or worse. In the 60 Gy group, three 
(2·3%) of 132 men had bowel side-eﬀ ects and ten (7·6%) 
had bladder side-eﬀ ects of grade 2 or worse at the same 
point. One (0·8%) of 129 men assessed at 18 weeks in the 
57 Gy group had bowel side-eﬀ ects and nine (7·0%) had 
bladder side-eﬀ ects of grade 2 or worse. Grade 3 bladder 
side-eﬀ ects were reported by two patients who received 
57 Gy, and one patient in the 74 Gy group had a grade 4 
event. No acute grade 3 bowel toxicity was reported.
Late side-eﬀ ect proﬁ les by treatment group as reported 
on each scoring system are shown in ﬁ gures 3 and 4. 
Figure 2: Acute RTOG toxicity by timepoint and treatment group
Prevalence of bowel toxicity (A) and distribution of grades (B). Prevalence of bladder toxicity (C) and distribution of grades (D). RTOG=Radiation Therapy Oncology Group scale. G1+=score of grade 1 or 
worse. G2+=score of grade 2 or worse. G3+=score of grade 3 or worse.
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Figure 3: Bowel toxicity of the three treatment groups by assessment timepoint
Cumulative proportion measured with RTOG (A), RMH (D), and LENT/SOM (G). Prevalence measured with RTOG (B), RMH (E), and LENT/SOM (H). Distribution of grade scores with RTOG (C), RMH (F), and 
LENT/SOM (I). RTOG=Radiation Therapy Oncology Group scale. RMH=Royal Marsden Hospital scale. LENT/SOM=Late Eﬀ ects on Normal Tissue: Subjective/Objective/Management scale. G1+=score of 
grade 1 or worse. G2+=score of grade 2 or worse. G3+=score of grade 3 or worse. G0=score of grade 0. G1=score of grade 1. G2=score of grade 2. PH=before hormone treatment. PR=before radiotherapy.
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Figure 4: Bladder toxicity of the three treatment groups by assessment timepoint
Cumulative proportion measured with RTOG (A), RMH (D), and LENT/SOM (G). Prevalence measured with RTOG (B), RMH (E), and LENT/SOM (H). Distribution of grade scores with RTOG (C), RMH (F), 
and LENT/SOM (I). RTOG=Radiation Therapy Oncology Group scale. RMH=Royal Marsden Hospital scale. LENT/SOM=Late Eﬀ ects on Normal Tissue: Subjective/Objective/Management scale. PH=before 
hormone treatment. PR=before radiotherapy. G1+=score of grade 1 or worse. G2+=score of grade 2 or worse. G3+=score of grade 3 or worse. G0=score of grade 0. G1=score of grade 1. G2=score of 
grade2. PH=before hormone treatment. PR=before radiotherapy.
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RTOG toxicity scores at 2 years were available for 138 men 
given 74 Gy, 137 given 60 Gy, and 143 given 57 Gy. 
Six (4·3%; 95% CI 1·6–9·2) of 138 men in the 74 Gy 
group had RTOG bowel toxicity of grade 2 or worse at 
2 years, as did ﬁ ve (3·6%; 1·2–8·3) of 137 men in the 
60 Gy group and two (1·4%; 0·2–5·0) of 143 men in the 
57 Gy group. RTOG bladder toxicity of grade 2 or worse 
at 2 years was reported by three (2·2%; 0·5–6·2) of 
138 men in the 74 Gy group and three (2·2%; 0·5–6·3) of 
137 men in the 60 Gy group; no side-eﬀ ects of grade 2 or 
worse were reported in the 143 men in the 57 Gy group 
(97·5% one-sided CI 0·0–2·6). Grade 3 bladder toxicity 
was not observed, and grade 3 bowel toxicity was reported 
by one patient in the 60 Gy group at 2 years. None of the 
estimates of late toxicity suggested a doubling of side-
eﬀ ects in the experimental groups compared with the 
standard group and, because the upper conﬁ dence limits 
are all less than 20%, the criteria for rejection of any of 
the treatment groups on the grounds of safety were not 
met. Results from the sensitivity analysis that included 
all patients suggested that the ﬁ ndings are robust to 
missing outcomes (data not shown).
Total 
events
60 Gy vs 74 Gy 57 Gy vs 74 Gy Cumulative events and cumulative proportion of events at 2 years
HR (95% CI) p value HR (95% CI) p value 74 Gy (n=149) 60 Gy (n=147) 57 Gy (n=148)
Events % (95% CI) Events % (95% CI) Events % (95% CI)
Bowel
RTOG
Grade 1 or worse 150 0·76 (0·52–1·12) 0·169 0·72 (0·48–1·06) 0·091 45 30·6% (23·8–38·7) 40 27·6% (21·1–35·6) 37 25·2% (18·9–33·0)
Grade 2 or worse 36 0·93 (0·44–1·97) 0·845 0·62 (0·27–1·44) 0·270 11 7·6% (4·3–13·2) 10 6·9% (3·8–12·5) 7 4·8% (2·3–9·7)
Grade 3 or worse 4 0·99 (0·06–15·76) 0·992 1·94 (0·18–21·44) 0·587 0 ·· 1 0·7% (0·1–4·7) 1 0·7% (0·1–4·7)
RMH
Grade 1 or worse 203 0·92 (0·66–1·29) 0·640 0·89 (0·64–1·25) 0·511 53 36·1% (28·9–44·5) 55 37·9% (30·5–46·3) 52 35·3% (28·2–43·6)
Grade 2 or worse 47 1·19 (0·60–2·37) 0·608 0·90 (0·44–1·87) 0·785 10 6·9% (3·8–12·4) 11 7·6% (4·3–13·3) 10 6·8% (3·7–12·3)
Grade 3 or worse 10 0·25 (0·03–2·20) 0·210 1·23 (0·33–4·58) 0·757 3 2·1% (0·7–6·2) 1 0·7% (0·1–4·8) 3 2·0% (0·7–6·2)
LENT/SOM
Grade 1 or worse 239 0·87 (0·64–1·18) 0·374 0·76 (0·56–1·04) 0·089 69 46·9% (39·2–55·2) 64 44·3% (36·7–52·8) 62 42·2% (34·7–50·6)
Grade 2 or worse 97 0·88 (0·55–1·41) 0·593 0·78 (0·48–1·26) 0·308 25 17·1% (11·9–24·2) 23 16·0% (10·9–23·0) 23 15·7% (10·7–22·6)
Grade 3 or worse 15 0·34 (0·07–1·63) 0·173 1·11 (0·37–3·32) 0·846 3 2·1% (0·7–6·2) 1 0·7% (0·1–4·7) 4 2·7% (1·0–7·1)
Grade 4 or worse 1 – – – – 0 ·· 0 ·· 1 0·7% (0·1–4·7)
Bladder
RTOG
Grade 1 or worse 82 1·15 (0·69–1·93) 0·597 0·85 (0·49–1·47) 0·553 18 12·3% (7·9–18·8) 25 17·4% (12·1–24·6) 16 10·9% (6·8–17·1)
Grade 2 or worse 37 1·74 (0·79–3·79) 0·167 0·99 (0·41–2·37) 0·978 5 3·5% (1·5–8·1) 13 9·0% (5·4–15·1) 7 4·8% (2·3–9·8)
Grade 3 or worse 14 2·62 (0·70–9·91) 0·155 0·97 (0·20–4·80) 0·969 2 1·4% (0·4–5·4) 6 4·2% (1·9–9·0) 1 0·7% (0·1–4·7)
RMH
Grade 1 or worse 301 0·79 (0·60–1·05) 0·099 1·01 (0·77–1·32) 0·946 93 63·1% (55·4–70·9) 75 51·7% (43·8–60·0) 91 61·7% (54·0–69·6)
Grade 2 or worse 91 0·92 (0·56–1·51) 0·740 0·83 (0·50–1·37) 0·469 17 11·7% (7·4–18·1) 20 13·8% (9·1–20·6) 18 12·3% (7·9–18·8)
Grade 3 or worse 29 1·24 (0·51–2·99) 0·631 0·98 (0·39–2·48) 0·958 7 4·8% (2·3–9·8) 9 6·2% (3·3–11·7) 5 3·4% (1·4–8·0)
LENT/SOM
Grade 1 or worse 331 0·77 (0·59–1·00) 0·049 0·76 (0·59–0·99) 0·044 106 72·2% (64·7–79·2) 93 64·4% (56·6–72·1) 95 64·7% (57·0–72·3)
Grade 2 or worse 202 0·86 (0·62–1·19) 0·361 0·70 (0·50–0·98) 0·040 60 40·9% (33·4–49·3) 61 42·3% (34·7–50·7) 46 31·3% (24·5–39·5)
Grade 3 or worse 68 1·28 (0·72–2·28) 0·396 0·98 (0·53–1·79) 0·940 11 7·5% (4·3–13·2) 16 11·1% (6·9–17·4) 15 10·3% (6·3–16·4)
Grade 4 or worse 12 0·75 (0·17–3·37) 0·713 1·19 (0·32–4·42) 0·799 3 2·1% (0·7–6·2) 3 2·1% (0·7–6·3) 3 2·1% (0·7–6·2)
Sexual dysfunction
LENT/SOM
Grade 1 or worse 424 1·02 (0·81–1·29) 0·879 0·94 (0·75–1·19) 0·633 140 95·0% (90·5–97·8) 137 94·4% (89·7–97·3) 133 90·5% (85·1–94·6%)
Grade 2 or worse 414 1·06 (0·84–1·35) 0·612 1·00 (0·79–1·27) 0·992 134 91·0% (85·6–94·9) 132 90·9% (85·5–94·8) 131 89·3% (83·6–94·8%)
Grade 3 or worse 389 1·06 (0·83–1·35) 0·662 1·06 (0·83–1·35) 0·648 118 80·0% (73·2–86·0) 116 79·8% (72·9–85·8) 120 81·8% (75·1–87·5%)
Grade 4 or worse 337 1·11 (0·86–1·45) 0·427 1·02 (0·79–1·33) 0·858 95 64·6% (56·8–72·2) 102 70·1% (62·6–77·3) 95 64·6% (56·9–72·2%)
HR=hazard ratio. RTOG=Radiation Therapy Oncology Group scale. –=Insufficient events to estimate HR. RMH=Royal Marsden Hospital scale. LENT/SOM=Late Effects on Normal Tissue: Subjective/
Objective/Management scale. HRs include all late events reported. Cumulative proportion figures only include events occurring up to 2 years post-radiotherapy and are calculated with the Kaplan-Meier 
method.
Table 2: Total number of events, hazard ratios, and cumulative proportion with events by 2 years for bowel, bladder, and sexual dysfunction endpoints by allocated treatment group
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Results of exploratory comparative analyses of cumu-
lative incidence are shown in table 2. The cumulative 
proportion of patients with late RTOG bowel toxicity of 
grade 2 or worse at 2 years was 7·6% (95% CI 4·3–13·2) 
in the 74 Gy group, 6·9% (3·8–12·5) in the 60 Gy group, 
and 4·8% (2·3–9·7) in the 57 Gy group (ﬁ gure 3; table 2). 
For late RTOG bladder toxicity, cumulative proportion 
values were 3·5% (1·5–8·1), 9·0% (5·4–15·1), and 4·8% 
(2·3–9·8; ﬁ gure 4, table 2). There were no statistically 
signiﬁ cant diﬀ erences in cumulative incidence of side-
eﬀ ects between the groups.
With the RMH symptom score, there was low 
prevalence of bowel scores of grade 2 or worse before 
radiotherapy on either of the baseline scores (ie, before 
hormone or radiotherapy treatment; eight of 451 patients). 
At 2 years, eight (5·8%) of 138 patients given 74 Gy had 
RMH bowel scores of grade 2 or worse, four (2·9%) of 
138 patients given 60 Gy, and one (0·7%) of 143 patients 
given 57 Gy. 40 (28·9%) of 138 men given 74 Gy, 25 (18·1%) 
of 138 given 60 Gy, and 29 (20·3%) of 143 given 57 Gy had 
RMH scores of grade 1 or worse. Prevalences of bladder 
scores of grade 2 or worse were similar in the three 
groups before radiotherapy: 25 (17·2%) of 145 men given 
74 Gy, 22 (15·1%) of 146 given 60 Gy, and 21 (14·7%) of 
143 given 57 Gy. After 2 years, 15 (10·8%) of 139 men 
given 74 Gy, nine (6·5%) of 138 given 60 Gy, and nine 
(6·3%) of 143 given 57 Gy had bladder scores of grade 2 
or worse (ﬁ gure 4). RMH bladder scores of grade 1 or 
worse were recorded in 61 (43·9%) of 139 men given 74 
Gy, 39 (28·3%) of 138 given 60 Gy, and 50 (35·0%) of 143 
given 57 Gy.
With the LENT/SOM assessment system and the 
maximum score for each normal tissue, the prevalence 
of bowel scores of grade 2 or worse before hormone or 
radiotherapy treatments was 3·9% (17 of 439 patients). 
Grade 1 scores or worse were reported in 19 (13·5%) of 
141 patients in the 74 Gy group, 16 (11·0%) of 146 in the 
60 Gy group, and 15 (10·6%) of 142 in the 57 Gy group 
at the assessment before radiotherapy. The prevalence 
of bowel symptoms at 2 years was higher in the 74 Gy 
group than in the other two groups, with 31 (22·5%) of 
138 patients in the 74 Gy group experiencing grade 1 
events, 13 (9·4%) experiencing grade 2 events, and two 
(1·4%) experiencing grade 3 events versus 23 (16·8%) 
of 137 men in the 60 Gy group experiencing grade 1 
events, seven (5·1%) experi encing grade 2 events, and 
one (0·7%) experiencing grade 3 events, and 22 (15·5%) 
of 142 men in the 57 Gy group experiencing grade 1 
events, six (4·2%) experi encing grade 2 events, and one 
(0·7%) experiencing grade 3 events (p=0·023). The 6, 
12, 18, and 24 month scores after radiotherapy all 
showed signiﬁ cant increases compared to pre-
radiotherapy levels (p=0·0001 for 6 month scores; 
p<0·0001 for other timepoints).
Before hormone treatment, 45 (18·8%) of 239 patients 
had LENT/SOM grade 1 bladder scores, 61 (25·5%) had 
grade 2 scores, and 26 (10·9%) had grades 3 or 4. 
Prevalences were similar before radiotherapy treatment 
across the three randomised groups (ﬁ gure 4). Scores 
were lower at 6, 12, 18, and 24 months than they were 
before radiotherapy (p<0·0001 at all timepoints). 
At 2 years,  28 (20·4%) of 137 men in the 74 Gy group had 
grade 1 scores, as did 25 (18·2%) of 137 in the 60 Gy group 
and 28 (19·7%) of 142 in the 57 Gy group. Additionally, 
21 (15·3%) men given 74 Gy, 17 (12·3%) given 60 Gy, and 
17 (12·0%) given 57 Gy had grade 2 scores. Six (4·4%) in 
the ﬁ rst group, eight (5·8%) in the second, and ﬁ ve 
(3·5%) in the third were grade 3 or worse.
Figure 5: LENT/SOM sexual dysfunction toxicity of the three treatment groups by assessment timepoint
(A) Cumulative proportion. (B) Prevalence. (C) Distribution of grades. LENT/SOM=Late Eﬀ ects on Normal Tissue: Subjective/Objective/Management scale. G1+=score of grade 1 or worse. G2+=score of 
grade 2 or worse. G3+=score of grade 3 or worse. G0=score of grade 0. G1=score of grade 1. G2=score of grade 2. G3=score of grade 3. G4=score of grade 4. PH=before hormone treatment. PR=before 
radiotherapy.
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Before hormone treatment, sexual dysfunction (a score 
greater than 2 on the LENT/SOM scale) was recorded in 
102 (43·6%) of 234 men. As expected, scores deteriorated 
during neoadjuvant hormone therapy, with 350 (83·5%) 
of 419 men recording scores of grade 2 or worse before 
radiotherapy (p<0·0001). Partial recovery was reported: 
scores of grade 2 or worse were reported in 310 (75·4%) 
of 411 patients 24 months after radiotherapy treatment 
(ﬁ gure 5). LENT/SOM sexual dysfunction scores were 
not signiﬁ cantly diﬀ erent in randomised groups at any 
point (table 2).
Discussion
This planned interim analysis of stages 1 and 2 of 
the CHHiP trial has shown no clinically meaningful 
diﬀ erences in acute toxicity between standard and 
hypofractionated radiotherapy schedules. Preliminary 
safety assessment of late side-eﬀ ects to 2 years raised no 
concerns about the safety of the experimental treatments 
as delivered in a multicentre trial setting. The safety 
criteria for stopping were not met and the trial completed 
accrual in June, 2011.
Acute reactions occurred earlier in the hypofractionated 
groups than in the control group, in which the pattern of 
acute toxicity was very similar to that reported in the 
group of men randomised to receive 74 Gy in a previous 
trial.17 However, the cumulative proportion of both bowel 
and bladder side-eﬀ ects at 2 years is lower in the CHHiP 
trial than in the 74 Gy group in the previous trial (in 
which incidence of RTOG bowel toxicity of grade 2 or 
worse was 20% and bladder toxicity of grade 2 or worse 
was 8%).20 This diﬀ erence might be a result of patient 
selection factors (although age and PSA distributions 
are very similar), or of the favourable dose distributions 
and adherence to normal tissue dose constraints with 
the forward-planning or inverse-planning methods used 
in the CHHiP trial.15 Data from randomised controlled 
trials have shown that treatment technique,21 planning 
target margin,22 and dose,22–26 can all aﬀ ect outcomes of 
prostate cancer radiotherapy. Therefore, meaningful 
assessment of the biological eﬀ ects of altered 
fractionation schedules can be made only by controlling 
for these other factors.
Although not included as part of this safety analysis, 
we have measured patient-reported outcomes with the 
same instruments as those used in the previous trial.17 
This continuing longitudinal quality-of-life substudy that 
recruited 1958 men will help to establish whether altered 
fractionation aﬀ ects diﬀ erent symptom complexes27 and 
will be analysed and published separately.
The choice of treatment in our control group was based 
on level 1 evidence and a meta-analysis of trials assessing 
dose escalation6 and the addition of hormonal therapy28,29 
for men with intermediate-risk and high-risk disease. 
The dose of 74 Gy was preferred to a higher dose because 
it has become the standard dose in the UK7 after the MRC 
RT01 trial,20 which is the largest reported study of dose 
escalation and the only study to routinely include short-
course androgen suppression. The median duration of 
androgen suppression of 5 months is roughly what was 
recommended in the updated TROG 96.01 trial that 
compared radiotherapy alone with the addition of either 
3 or 6 months of androgen deprivation.30
The experimental high-dose hypofractionated groups 
were designed as they were because retrospective data 
reviews have suggested that the α-β ratio might be low 
(panel).8,10 Large multicentre reviews and a meta-
summary33–35 have suggested estimates of 3·7 Gy,34 and 
1·4 Gy.33 However, a 2008 review36 of studies that used 
altered hypofractionated treatments showed that evidence 
is insuﬃ  cient to recommend a change to doses larger 
than 2 Gy per fraction and that results from continuing 
randomised controlled trials were needed. 4 week 
schedules with 3 Gy fractions were chosen because there 
was some data and experience with similar, but lower 
dose schedules in the UK.37
Other investigators of international studies of hypo-
fractionated radiotherapy have also reported favourable 
toxicity. A small Italian phase 3 trial38 included 168 men 
and was designed to establish whether a high-dose 
hypofractionation schedule (62 Gy in 3·1 Gy daily 
fractions) was associated with lower radiation-related 
toxicity than was a high-dose conventional schedule 
(80 Gy in 2 Gy daily fractions). Frequency of side-eﬀ ects 
after 3 years of follow-up and PSA control was reported to 
be at least as good in the hypofractionated cohort as in 
the control group (PSA control 87% vs 79%, p=0·04).38 
Additionally, reports from phase 1 or 2 trials of high-dose 
hypofractionated radiotherapy treatments in prostate 
cancer are encouraging. Three reports39–41 document 
schedules of 3 Gy per fraction to give total doses of 
Panel: Research in context
Systematic review
Before the CHHiP trial began, reports based on retrospective series of patients suggested 
that the α-β ratio for prostate cancer might be low,8–10 but only two small randomised 
trials (with relatively low doses of radiotherapy) existed and neither was large enough to 
conﬁ rm or refute a beneﬁ t.31,32 Since CHHiP started, reviews33,34 of two large patient 
databases have been done, suggesting that the best estimates for the α-β ratio are 3·7 Gy 
and 1·4 Gy. However, these retrospective analyses and reviews have not changed clinical 
practice, hence the need for a randomised controlled trial. Dose escalation and 
neoadjuvant androgen deprivation improve disease control, but dose escalation increases 
bowel side-eﬀ ects. However, conformal and intensity-modulated radiotherapy improves 
dose distributions of radiotherapy and conformal radiotherapy reduces side-eﬀ ects.
Interpretation
The ﬁ ndings from this pre-planned safety analysis of the ﬁ rst 457 patients enrolled in the 
CHHiP trial suggest that high-dose hypofractionated schedules using 3 Gy fractions and 
intensity-modulated radiotherapy are safe. Safety and eﬃ  cacy data from the full trial is 
essential to fully assess hypofractionated schedules, but these safety results should enable 
investigators to safely pursue these avenues of research. Clinicians and patients should be 
strongly encouraged to support trials using fractions of 3 Gy or more.
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57–60 Gy. Late bowel side-eﬀ ects (RTOG grade 2 or worse) 
have been reported in 4%, 5·5%, and 6·3% and late 
bladder side-eﬀ ects in 4·2%, 5·6%, and 4·3%  of men 
after 2–5 years of follow-up.39–41 A preliminary report37 of a 
dose-fractionation escalation study in 210 men (2·94 Gy 
in 22 fractions to 4·3 Gy in 12 fractions) reported rectal 
bleeding in 8·8% of patients. In a large phase 2 study 
including 770 men treated with 2·5 Gy fractions to a total 
of 70 Gy in 5·5 weeks,42 rates of late grade 2 or worse 
rectal and bladder toxicity were 4·5% and 5·2%.
Preliminary estimates of PSA control rates in these 
studies38–42 are comparable to those in standard fractionation 
schedules. A large single-institute series of 705 men in 
Manchester, UK, is valuable, because it suggests that a 
schedule of 50 Gy in 16 fractions (3·125 Gy per fraction) 
was equivalent to a contem poraneously treated series with 
65–70 Gy in 1·8–2·0 Gy fractions.43 Previously reported 
randomised controlled trials of hypofractionation have 
used only modest radiation doses by present standards. 
A phase 3 trial31 in 936 men has compared 52·5 Gy in 
20 fractions to 66 Gy in 33 fractions. Results show a 7% 
reduction in PSA control rate (52·95% vs 59·95%) in the 
20 fraction group with HR for failure of 1·18 (95% CI 
0·99–1·41). Late grade 3 or 4 toxicity was roughly 3% in 
the two groups. A second randomised controlled trial32 of 
120 men compared a dose of 64 Gy in 32 fractions with 
55 Gy in 20 fractions. After median follow-up of 44 months, 
4 year PSA control rates were alike (86·2% for hypo-
fractionation vs 85·4% for standard fractionation); rectal 
bleeding was more frequent in the hypofractionated group 
(appendix). All these studies are compatible with an 
α-β ratio for prostate cancer of 1·5–3·0 Gy.44
Other phase 3 randomised controlled trials are under-
way: in Canada, investigators are comparing 60 Gy in 
20 fractions with 78 Gy in 39 fractions in a planned cohort 
of 1204 patients (ISRCTN 43853433); and in the 
Netherlands, researchers are comparing 64·6 Gy in 
19 fractions with 78 Gy in 39 fractions, with a planned 
cohort of 800 patients (ISRCTN 85138529). The Dutch 
study regimen treats in 7 weeks rather than 4 weeks to 
keep the total treatment time constant, avoiding the 
possible time-related increase in damage. After a pilot 
study, a Scandinavian collaborative group is comparing 
increased hypofractionation with 42·7 Gy in seven 
fractions given in 15–19 days with 78 Gy in 39 fractions 
in 7·8 weeks in a group of 592 men (ISRCTN 45905321). 
The combination of studies should clearly deﬁ ne the 
clinical role of hypofractionation for prostate cancer and 
the fractionation sensitivity of both prostate cancer and 
normal tissues with improved precision.
Analyses in our study were not powered for formal 
comparisons and 84% of patients were from two sites, 
although the trial occurred in 11 centres overall. Therefore, 
comparisons of toxicity data by fractionation schedules are 
preliminary. Stage 3 of this trial aims to show non-inferiority 
of biochemical PSA control between experimental and 
control groups and includes an additional 2759 patients 
recruited from 41 centres, and will provide an opportunity 
to validate the ﬁ ndings presented here. Planned associated 
translational research includes comparative dose-volume 
histograms and side-eﬀ ect analysis for the hypofractionated 
groups, collection of germline DNA for radiogenomics,45 
and tissue microarray assessment of predictive factors for 
fraction sensitivity.
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